Polaris Group (6550.TW)
TWD 37.6
(1.9%)
TWD 37.6
(1.9%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.57 Billion TWD | -37.05% |
| 2022 | -1.15 Billion TWD | -55.36% |
| 2021 | -740.48 Million TWD | -12.16% |
| 2020 | -660.22 Million TWD | 20.43% |
| 2019 | -829.75 Million TWD | 19.62% |
| 2018 | -1.03 Billion TWD | -14.89% |
| 2017 | -898.45 Million TWD | 8.55% |
| 2016 | -982.45 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -390.65 Million TWD | 28.2% |
| 2024 Q2 | -562.02 Million TWD | -40.91% |
| 2023 Q4 | -544.12 Million TWD | -27.98% |
| 2023 Q1 | -273.94 Million TWD | 5.11% |
| 2023 FY | -1.57 Billion TWD | -37.05% |
| 2023 Q2 | -334.42 Million TWD | -22.08% |
| 2023 Q3 | -425.16 Million TWD | -27.13% |
| 2022 Q3 | -306.15 Million TWD | -4.51% |
| 2022 FY | -1.15 Billion TWD | -55.36% |
| 2022 Q4 | -288.71 Million TWD | 5.7% |
| 2022 Q2 | -292.93 Million TWD | -11.54% |
| 2022 Q1 | -262.62 Million TWD | 0.0% |
| 2021 FY | -740.48 Million TWD | -12.16% |
| 2020 FY | -660.22 Million TWD | 20.43% |
| 2019 FY | -829.75 Million TWD | 19.62% |
| 2018 FY | -1.03 Billion TWD | -14.89% |
| 2017 FY | -898.45 Million TWD | 8.55% |
| 2016 FY | -982.45 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 115.78 Million TWD | 1461.766% |
| Sinphar Pharmaceutical Co.,Ltd. | 375.17 Million TWD | 520.261% |
| Panion & Bf Biotech Inc. | 77.21 Million TWD | 2141.847% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 264.9 Million TWD | 695.183% |
| GenMont Biotech Incorporation | 32.99 Million TWD | 4879.164% |
| Abnova (Taiwan) Corporation | 43.67 Million TWD | 3709.813% |
| Adimmune Corporation | -639.89 Million TWD | -146.4% |
| Tanvex BioPharma, Inc. | -2.13 Billion TWD | 26.223% |
| Energenesis Biomedical CO.,LTD. | -260.38 Million TWD | -505.531% |
| UnicoCell Biomed Co., Ltd. | -84.1 Million TWD | -1774.606% |
| PELL Bio-Med Technology Co. Ltd. | -398.75 Million TWD | -295.403% |